133 related articles for article (PubMed ID: 356720)
1. Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia.
Koskinen P; Inkovaara J; Ala-Kaila K; Salo M; Nikkari T
Ann Clin Res; 1977 Dec; 9(6):335-41. PubMed ID: 356720
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
Arntz HR; Klemens UH; Vollmar LJ; Lang PD
Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
[TBL] [Abstract][Full Text] [Related]
3. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
Wilke H; Frahm H
Dtsch Med Wochenschr; 1976 Mar; 101(11):401-5. PubMed ID: 1253701
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of the combination of calcium clofibrate and calcium carbonate on serum total cholesterol, triglyceride and high density lipoprotein--cholesterol concentrations in hyperlipoproteinaemia. A comparative study with clofibrate.
Lehtonen A; Viikari J
Atherosclerosis; 1979 May; 33(1):49-58. PubMed ID: 223601
[TBL] [Abstract][Full Text] [Related]
6. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Orö L; Olsson AG; Rössner S; Carlson LA
Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
[TBL] [Abstract][Full Text] [Related]
8. [Modification of serum lipids, lipoproteins and apoproteins AI and B in patients with hyperlipidemia Type IIa and IIb using polyenylphosphatidylcholine].
Noseda G; Suvà F; Fragiacomo C
Schweiz Med Wochenschr; 1985 Jul; 115(30):1064-70. PubMed ID: 4035328
[TBL] [Abstract][Full Text] [Related]
9. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J
Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549
[TBL] [Abstract][Full Text] [Related]
11. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
Bucalossi A; Buzzelli G; D'Alessandro A
Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
[No Abstract] [Full Text] [Related]
12. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
13. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)].
Schwartzkopff W; Russ E
MMW Munch Med Wochenschr; 1975 May; 117(19):827-30. PubMed ID: 805950
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
[TBL] [Abstract][Full Text] [Related]
15. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
[TBL] [Abstract][Full Text] [Related]
16. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye ER; Sutherland WH; Temple Wa
N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
Haacke H; Parwaresch MR; Mäder C
Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
[TBL] [Abstract][Full Text] [Related]
18. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
Jantke J; Schwartzkopff W; Zschiedrich M
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
[No Abstract] [Full Text] [Related]
20. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
